Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
Koichi HirataTakao TakeshimaFumihiko SakaiYotaro NumachiRyuji YoshidaReija KoukakisMiki HasebeDaishi YuiGabriel Paiva da Silva LimaSunfa ChengPublished in: BMJ open (2023)
NCT03812224.